menu
    • menu
    [{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Perflutren","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Zavegepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Goldman Sachs","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pharma \/ Goldman Sachs"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ Not Applicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Flatley Discovery Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vatiquinone","moa":"15-LOX","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Flatley Discovery Lab","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flatley Discovery Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Flatley Discovery Lab \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"DNL343","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"E2814","moa":"MTBR-tau","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Not Applicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Maryland Board of Public Works","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Maryland Board of Public Works","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Maryland Board of Public Works"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ George Clinical","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ George Clinical"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trehalose API","moa":"TFEB","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund LTV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund LTV","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund LTV"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund Ltd."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma 1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Not Applicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"DNL343","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aural Analytics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Aural Analytics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aural Analytics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aural Analytics \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Basimglurant","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0.11,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"","sponsorNew":"Noema Pharma \/ Forbion","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Forbion"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SLS-005","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"DNL343","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Multiple Sclerosis Society","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ National Multiple Sclerosis Society","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ National Multiple Sclerosis Society"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Vivo Capital","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Vivo Capital"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mesdopetam","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Canaccord Genuity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Mediforum","sponsor":"Vision Sensing Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"PM012","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Mediforum","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mediforum \/ Vision Sensing Acquisition Corp.","highestDevelopmentStatusID":"9","companyTruncated":"Mediforum \/ Vision Sensing Acquisition Corp."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Trehalose API","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ACP-204","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Group \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"DNL343","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sabirnetug","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sabirnetug","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Rinvecalinase Alfa","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"DiaMedica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"NIH","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ NIH","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ NIH"}]

    Find Neurology Drugs in Phase II/III Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Annovis Bio

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Annovis Bio

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buntanetap

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving The Way to NDAs

                            Details : ANVS401 (buntanetap) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, thereby improving synaptic transmission in patients with Alzheimer’s Disease.

                            Brand Name : ANVS401

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 15, 2024

                            Lead Product(s) : Buntanetap

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Clene Nanomedicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Clene Nanomedicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : SymBiosis

                            Deal Size : $7.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Clene Closes $7.3M Offering and Amends Debt Facility for Ongoing Initiatives

                            Details : The proceeds will be used to file a new drug application under the accelerated approval pathway for CNM-Au8, a catalytically active gold nanocrystal suspension.

                            Brand Name : CNM-Au8

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : SymBiosis

                            Deal Size : $7.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medicinova

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Medicinova

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibudilast

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MediciNova to Support Expanded ALS Trial with MN166

                            Details : MN-166 (ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines, including MIF. It is being developed for ALS.

                            Brand Name : MN166

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 30, 2024

                            Lead Product(s) : Ibudilast

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sage Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Sage Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAGE-324

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Biogen

                            Deal Size : $1,525.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Sage Therapeutics Ends Collaboration with Biogen on SAGE-324 Program

                            Details : Following the termination of the agreement, Sage will regain full ownership of the SAGE-324 from Biogen. This asset is being evaluated for the treatment of patients with essential tremors.

                            Brand Name : SAGE-324

                            Molecule Type : Small molecule

                            Upfront Cash : $1,525.0 million

                            September 26, 2024

                            Lead Product(s) : SAGE-324

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Biogen

                            Deal Size : $1,525.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lonza Group

                            Switzerland arrow
                            BMWS24
                            Not Confirmed

                            Lonza Group

                            Switzerland arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sabirnetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Acumen Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Acumen Pharma Extends Lonza Collaboration for Drug Manufacturing of Sabirnetug

                            Details : Acumen collaborates with Lonza to advance the clinical development and potential future commercial launch of ACU193 (sabirnetug), which is being evaluated for Alzheimer’s disease.

                            Brand Name : ACU193

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 26, 2024

                            Lead Product(s) : Sabirnetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Acumen Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Clene Nanomedicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Clene Nanomedicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clene Granted Meeting with FDA to Discuss CNM-Au8 Biomarker Data

                            Details : CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.

                            Brand Name : CNM-Au8

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 16, 2024

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PharmaTher

                            Canada arrow
                            BMWS24
                            Not Confirmed

                            PharmaTher

                            Canada arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaTher Announces Update on FDA New Drug Application for Ketamine

                            Details : Ketamine is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.

                            Brand Name : Ketamine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 04, 2024

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Athira Pharma

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Athira Pharma

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosgonimeton

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Athira Pharma's Alzheimer's Drug Fails in Mid-To-Late Stage Trial

                            Details : ATH-1017 (fosgonimeton) is a potentially first-in-class, investigational, small molecule designed to positively modulate HGF system. It is being evaluated for mild-to-moderate Alzheimer’s Disease.

                            Brand Name : ATH-1017

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : Fosgonimeton

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cessatech

                            Denmark arrow
                            BMWS24
                            Not Confirmed

                            Cessatech

                            Denmark arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride,Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Proveca

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cessatech and Proveca Announce World-wide Excluding US Commercial Partnership for CT001

                            Details : Under the agreement, Proveca will be the marketing authorization holder of CT001 worldwide excluding the US, which is being evaluated in the late stage for the treatment of Acute Pain in children.

                            Brand Name : CT001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 26, 2024

                            Lead Product(s) : Ketamine Hydrochloride,Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Proveca

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Clene Nanomedicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Clene Nanomedicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clene Submits New Biomarker and Clinical Efficacy Data for CNM-Au8® in ALS

                            Details : CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, in development for amyotrophic lateral sclerosis.

                            Brand Name : CNM-Au8

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 06, 2024

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth